AIM ImmunoTech Inc. is a biotechnology and immuno-pharmaceutical company specializing in the development of novel therapeutics for multiple cancers, immune disorders, and viral infections including COVID-19. Its flagship product, Ampligen®, is an RNA-based immuno-modulatory drug with broad-spectrum activity, currently undergoing advanced clinical trials for oncology applications such as pancreatic and ovarian cancers, as well as chronic conditions like myalgic encephalomyelitis/chronic fatigue syndrome and Long COVID. Ampligen works by reprogramming the tumor microenvironment to enhance immune responses, potentially improving outcomes when combined with other immunotherapies. The company also markets Alferon N Injection®, a natural interferon therapy approved for refractory genital warts and certain infections. With a robust pipeline, substantial clinical data, global patent protection, and a strong cash position, AIM ImmunoTech plays an innovative role in immunotherapy, targeting critical unmet medical needs through its research and development initiatives.